diclofenac has been researched along with Blood Clot in 19 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was performed to investigate, in an animal model of arterial thrombosis in vivo, whether diclofenac differentially influences platelet activation and thrombosis in vessels under non-stimulated conditions or during acute systemic inflammation, such as induced by tumor necrosis factor-alpha (TNF-alpha)." | 7.75 | Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. ( Buerkle, MA; Hellwig, N; Klauss, V; Krötz, F; Mannell, H; Pircher, J; Pohl, U; Sohn, HY; Struthmann, L, 2009) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "We evaluated the relationship between baseline BP and change in BP on CV events (CVEs) in patients receiving NSAIDs or COX-2 inhibitors in the prospective randomized, double-blind, Multinational Etoricoxib and Diclofenac Arthritis Long-term Program (N = 34,701) comparing etoricoxib 60 or 90 mg or diclofenac 150 mg daily for a mean duration of 18 months." | 5.16 | Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. ( Brater, DC; Cannon, CP; Curtis, SP; Gammaitoni, A; Kaur, A; Krum, H; Laine, L; Peloso, PM; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2012) |
| " PP-g-(NIPAAm-r-APMA) films showed temperature-responsive swelling, smaller friction coefficients, hemolysis and thrombogenicity and higher cell compatibility, did not elicit secretion of cytokines, and took up remarkable amounts of diclofenac and ibuprofen and sustained delivery for several hours in phosphate buffer, pH 7." | 3.77 | Stimuli-responsive networks grafted onto polypropylene for the sustained delivery of NSAIDs. ( Alvarez-Lorenzo, C; Bucio, E; Concheiro, A; Contreras-García, A; Taboada, C, 2011) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| "The study was performed to investigate, in an animal model of arterial thrombosis in vivo, whether diclofenac differentially influences platelet activation and thrombosis in vessels under non-stimulated conditions or during acute systemic inflammation, such as induced by tumor necrosis factor-alpha (TNF-alpha)." | 3.75 | Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. ( Buerkle, MA; Hellwig, N; Klauss, V; Krötz, F; Mannell, H; Pircher, J; Pohl, U; Sohn, HY; Struthmann, L, 2009) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "Pretreatment of rats by the cyclooxygenase inhibitors diclofenac, phenylbutazone, and aminophenazone did not influence kappa-carrageenin (KC) rat tail thrombosis (RTT) whereas pretreatment by aspirin, at high doses, and particularly sulfinpyrazone decreased RTT frequency, PGI2 or iloprost i." | 3.67 | Role of eicosanoids in the kappa-carrageenin rat tail thrombosis. ( Bekemeier, H; Hirschelmann, R, 1988) |
| " The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0." | 2.74 | Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). ( Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C, 2009) |
| " The present prospective, placebo-controlled and double-blind study aimed to evaluate the analgesic efficacy of diclofenac, a non-steroid anti-inflammatory drug (NSAID), in combination with paracetamol and opioids." | 2.71 | Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction. ( Legeby, M; Olofsson, C; Sandelin, K; Wickman, M, 2005) |
| " Collagen and U46619 caused in vivo thrombus formation with the former, but not latter, sensitive to oral dosing with aspirin." | 1.37 | Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. ( Armstrong, PC; Emerson, M; Kirkby, NS; Mitchell, JA; Warner, TD; Zain, ZN, 2011) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, J | 1 |
| Nadesalingam, K | 1 |
| Kirby, D | 1 |
| Vollaard, EJ | 1 |
| Kramers, C | 1 |
| Brouwers, JR | 1 |
| Combe, B | 1 |
| Swergold, G | 2 |
| McLay, J | 1 |
| McCarthy, T | 1 |
| Zerbini, C | 1 |
| Emery, P | 1 |
| Connors, L | 1 |
| Kaur, A | 3 |
| Curtis, S | 1 |
| Laine, L | 3 |
| Cannon, CP | 3 |
| Struthmann, L | 1 |
| Hellwig, N | 1 |
| Pircher, J | 1 |
| Sohn, HY | 1 |
| Buerkle, MA | 1 |
| Klauss, V | 1 |
| Mannell, H | 1 |
| Pohl, U | 1 |
| Krötz, F | 1 |
| Contreras-García, A | 1 |
| Alvarez-Lorenzo, C | 1 |
| Taboada, C | 1 |
| Concheiro, A | 1 |
| Bucio, E | 1 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Curtis, SP | 3 |
| Brune, K | 1 |
| Armstrong, PC | 1 |
| Kirkby, NS | 1 |
| Zain, ZN | 1 |
| Emerson, M | 1 |
| Mitchell, JA | 1 |
| Warner, TD | 1 |
| Krum, H | 1 |
| Gammaitoni, A | 1 |
| Peloso, PM | 1 |
| Smugar, SS | 1 |
| Brater, DC | 1 |
| Wang, H | 1 |
| Weir, MR | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Legeby, M | 1 |
| Sandelin, K | 1 |
| Wickman, M | 1 |
| Olofsson, C | 1 |
| Sibilia, J | 1 |
| Deray, G | 2 |
| Montalescot, G | 1 |
| Valat, JP | 1 |
| Héloire, F | 1 |
| Ko, AT | 1 |
| Bolognese, JA | 1 |
| Cavanaugh, PF | 1 |
| Reicin, AS | 2 |
| Einecke, D | 1 |
| Shapiro, D | 1 |
| Sperling, RS | 1 |
| Barr, E | 1 |
| Yu, Q | 1 |
| Bekemeier, H | 1 |
| Hirschelmann, R | 1 |
| Claros González, I | 1 |
| Baños Gallardo, M | 1 |
| Casal Alvarez, F | 1 |
| Argüelles Toraño, M | 1 |
| Campbell, WI | 1 |
| Watters, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for diclofenac and Blood Clot
| Article | Year |
|---|---|
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; | 2006 |
4 trials available for diclofenac and Blood Clot
| Article | Year |
|---|---|
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergenci | 2009 |
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Body Weight; Comorbidity; | 2012 |
Analgesic efficacy of diclofenac in combination with morphine and paracetamol after mastectomy and immediate breast reconstruction.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, | 2005 |
Venous sequelae following i.v. administration of diclofenac.
Topics: Adult; Arm; Diclofenac; Female; Hand; Humans; Injections, Intravenous; Male; Thrombosis; Veins | 1989 |
12 other studies available for diclofenac and Blood Clot
| Article | Year |
|---|---|
Diclofenac shouldn't be prescribed to people with heart problems, drug agency says.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Diclofenac; Drug and Narcotic Control; H | 2013 |
Cardiovascular safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebrovascular Disorders; Contraindications; Diclofenac; D | 2013 |
[Interaction between NSAIDs and acetylsalicylic acid disregarded].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Inte | 2014 |
Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arterioles; Cells, C | 2009 |
Stimuli-responsive networks grafted onto polypropylene for the sustained delivery of NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diclofenac; Hemolysis; Humans; Ibuprofe | 2011 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Collagen; Cycl | 2011 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
[Coronary risks with NSAID and coxibs. The end of hysteria].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause | 2006 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis.
Topics: Aminopyrine; Animals; Aspirin; Benzydamine; Cardiovascular Agents; Carrageenan; Diclofenac; Epoprost | 1988 |
[Systemic thrombotic microangiopathy secondary to diclofenac].
Topics: Diclofenac; Disseminated Intravascular Coagulation; Humans; Male; Microcirculation; Middle Aged; Thr | 1989 |